Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxae043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Pei Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Shanghai Scientific and Technological Committee, National Natural Science Foundation of China.
Abstract (Originalsprache)
Serum B-cell maturation antigen (sBCMA) levels can serve as a sensitive biomarker in multiple myeloma (MM). In the research setting, sBCMA levels can be accurately detected by enzyme-linked immunosorbent assay (ELISA), but the approach has not been approved for clinical use. Here, we used a novel chemiluminescence method to assess sBCMA levels in 759 serum samples from 17 healthy donors and 443 patients with plasma cell (PC) diseases including AL amyloidosis, POEMS syndrome, and MM. Serum BCMA levels were elevated 16.1-fold in patients with newly diagnosed MM compared to healthy donors and rare PC diseases patients. Specifically, the sBCMA levels in patients with progressive disease were 64.6-fold higher than those who showed partial response or above to treatment. The sBCMA level also correlated negatively with the response depth of MM patients. In newly diagnosed and relapsed MM patients, survival was significantly longer among those subjects whose sBCMA levels are below the median levels compared with those above the median value. We optimized the accuracy of the survival prediction further by integrating sBCMA level into the Second Revised International Staging System (R2-ISS). Our findings provide evidence that the novel chemiluminescence method is sensitive and practical for measuring sBCMA levels in clinical samples and confirm that sBCMA might serve as an independent prognostic biomarker for MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
- Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Förderung
- Shanghai Scientific and Technological Committee
- National Natural Science Foundation of China
Zitieren
APA
Guo, P., Wang, Y., He, H., Chen, D., Liu, J., Qiang, W., Lu, J., Liang, Y., & Du, J. (2024). Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae043
Vancouver
Guo P, Wang Y, He H, Chen D, Liu J, Qiang W, et al. Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxae043
BibTeX
@article{Guo2024,
author = {Guo, Pei and Wang, Yun and He, Haiyan and Chen, Dongjian and Liu, Jin and Qiang, Wanting and Lu, Jing and Liang, Yang and Du, Juan},
title = {Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxae043}
}
EUVIMED